BIOS - BioScrip, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.7100
-0.0100 (-0.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.7200
Open1.7100
Bid1.6200 x 2900
Ask1.7700 x 27000
Day's Range1.6800 - 1.7700
52 Week Range1.6800 - 4.1400
Volume1,239,076
Avg. Volume1,436,262
Market Cap219.145M
Beta (3Y Monthly)0.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Moody's2 days ago

    HC Group Holdings III, Inc. -- Moody's announces completion of a periodic review of ratings of HC Group Holdings III, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of HC Group Holdings III, Inc. New York, April 18, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of HC Group Holdings III, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Moving Average Crossover Alert: BioScrip
    Zacks4 days ago

    Moving Average Crossover Alert: BioScrip

    BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?
    Zacks6 days ago

    Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • New Strong Sell Stocks for April 11th
    Zacks9 days ago

    New Strong Sell Stocks for April 11th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • New Strong Sell Stocks for April 9th
    Zacks11 days ago

    New Strong Sell Stocks for April 9th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of BIOS earnings conference call or presentation 15-Mar-19 1:00pm GMT

    Q4 2018 BioScrip Inc Earnings and Definitive Merger Agreement with Option Care Call

  • Moody'slast month

    BioScrip, Inc. -- Moody's places BioScrip's ratings under review for upgrade following the announced merger with HC Group Holdings

    Moody's Investors Service ("Moody's") today placed the ratings of BioScrip, Inc. (BioScrip), including the Caa1 Corporate Family Rating (CFR), under review for upgrade. This follows the announcement that BioScrip will merge with HC Group Holdings III, Inc.(dba Option Care). BioScrip will issue common stock to Option Care in an all-stock deal.

  • MarketWatchlast month

    BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish

    Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-term pain, given the disappointment that BioScrip shareholders will own just 20% of the post-merger company, but he remains bullish given the long-term potential. "The need for scale in health care is increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close wrote in a research note. "Thus, having scale is a significant advantage as [BioScrip] seeks to negotiate rates and drive sustained operating results." The stock has tumbled 35.5% year to date, while the S&P 500 has climbed 12.7%.

  • BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract
    Zackslast month

    BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

    The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

  • Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?
    Zackslast month

    Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?

    Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.

  • Why Adobe, BioScrip, and Ascena Retail Group Slumped Today
    Motley Foollast month

    Why Adobe, BioScrip, and Ascena Retail Group Slumped Today

    Earnings and other bad news kept these stocks out of today's rally.

  • Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript

    BIOS earnings call for the period ending December 31, 2018.

  • Why BioScrip Stock Popped and Then Dropped Today
    Motley Foollast month

    Why BioScrip Stock Popped and Then Dropped Today

    BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.

  • TheStreet.comlast month

    Infusion Therapy Firm BioScrip to Buy Rival Option Care

    agreed to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S. On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.

  • MarketWatchlast month

    BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison Dearborn

    Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.

  • Associated Presslast month

    BioScrip: 4Q Earnings Snapshot

    The Denver-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • What Kind Of Shareholders Own BioScrip, Inc. (NASDAQ:BIOS)?
    Simply Wall St.last month

    What Kind Of Shareholders Own BioScrip, Inc. (NASDAQ:BIOS)?

    A look at the shareholders of BioScrip, Inc. (NASDAQ:BIOS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...

  • Here is What Hedge Funds Think About BioScrip Inc. (BIOS)
    Insider Monkey4 months ago

    Here is What Hedge Funds Think About BioScrip Inc. (BIOS)

    Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]

  • Why Is BioScrip (BIOS) Up 18.7% Since Last Earnings Report?
    Zacks4 months ago

    Why Is BioScrip (BIOS) Up 18.7% Since Last Earnings Report?

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat
    Zacks5 months ago

    BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat

    A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of BIOS earnings conference call or presentation 6-Nov-18 2:00pm GMT

    Q3 2018 BioScrip Inc Earnings Call

  • BioScrip (BIOS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks5 months ago

    BioScrip (BIOS) Reports Q3 Loss, Tops Revenue Estimates

    BioScrip (BIOS) delivered earnings and revenue surprises of -28.57% and 5.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    BioScrip: 3Q Earnings Snapshot

    The Denver-based company said it had a loss of 9 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss ...

  • BioScrip Grows on CORE Plan, Reimbursement Issues Persist
    Zacks6 months ago

    BioScrip Grows on CORE Plan, Reimbursement Issues Persist

    BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.

  • BioScrip (BIOS) Up 4.8% Since Last Earnings Report: Can It Continue?
    Zacks7 months ago

    BioScrip (BIOS) Up 4.8% Since Last Earnings Report: Can It Continue?

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.